Narcolepsy

ALKS 2680, an investigational orexin 2 receptor agonist, showed promise for improving sleep latency in patients with narcolepsy type 2 and idiopathic hypersomnia in a phase 1b study.

The newly initiated phase 3 trial follows a successful phase 2 study where treatment with pitolisant resulted in greater improvement on the Epworth Sleepiness Scale for Children and Adolescents than placebo.

The presence of a sleep disorder was associated with a nearly 2-fold increase in the risk of increased health care utilization, with specific odds associated with individual sleep disorders.

A meta-analysis on studies assessing FDA-approved dual orexin receptor antagonists for insomnia treatment highlighted a greater risk of adverse events, particularly for narcolepsy-like symptoms.

Mind Moments®, a podcast from NeurologyLive®, brings you an interview with Alcibiades Rodriguez, MD. [LISTEN TIME: 19 minutes]

TAK-861, an orexin receptor 2 agonist, demonstrated efficacy and safety in a phase 2b trial for narcolepsy type 1.

The associate professor, department of medicine, division of neurology, Institute of Medical Science, University of Toronto, shared his thoughts on potential therapies and expanding care options for sleep disorders in 2024. [WATCH TIME: 5 minutes]

In a phase 2 proof-of-concept study, IHL-42X, a drug for obstructive sleep apnea, more significantly reduced apnea-hypopnea index and oxygen desaturation index than placebo.

Data supported a positive causal association between narcolepsy and schizophrenia and a reverse causal relationship between narcolepsy and major depressive disorder.

A recent open-label study focused on vagus nerve stimulation therapy's effects on patients with narcolepsy revealed a specific and notable improvement in daytime sleepiness.

The associate professor, department of medicine, division of neurology, Institute of Medical Science, University of Toronto, discussed recent research that challenged the conventional definitions of sleep and how narcolepsy is often stigmatized. [WATCH TIME: 2 minutes]

A new study revealed daytime continuous polysomnography as a reliable and easily accessible diagnostic tool for identifying narcolepsy type 1 among pediatric patients.

Subgroups of narcolepsy types 1 and 2 had significant reductions in a number of secondary outcomes, including number of sleep stage transitions, number of nocturnal arousals, and improvements in sleep quality.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Jennifer Gudeman, PharmD. [LISTEN TIME: 17 minutes]

Pitolisant demonstrated a dose-dependent improvement in excessive daytime sleepiness and fatigue, with a safety profile that was consistent with previous studies. Additional data to be shared in early 2024.

The findings further supported the idea that prevention and assessment of cardiovascular risk in patients with narcolepsy is critical to ongoing care.

Brendon Yee, PhD, a respiratory and sleep physician at the Woolcock Institute of Medical Research, discussed findings from a recent phase 1 trial presented at World Sleep Congress 2023 in which ALKS 2680 demonstrated improvements in wakefulness among patients with narcolepsy type 1.

Preliminary data from a phase 1 study suggest that ALKS 2680, an investigational orexin 2 receptor agonist, is safe and improves sleep latency in narcolepsy patients, leading to plans for a phase 2 study.

Modius Sleep is designed to send a safe electrical pulse into the vestibular nerve, influencing the areas of the hypothalamus and brain stem that control circadian rhythm and sleep patterns.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is narcolepsy.

Presented at the 2023 World Sleep Congress, preclinical findings highlighted ORX750's potential as a novel treatment not only for narcolepsy type 1 but also for broader sleep-wake disorders, including narcolepsy type 2 and idiopathic hypersomnia.

A recent study assessing TAK-861, an orexin-type 2 receptor agonist, high and lose doses of the therapy demonstrated improvements in wakefulness compared with the placebo in healthy adult men.

A group of sleep experts discuss the importance of timely and accurate diagnosis, recent approvals, and available treatment options for managing a chronic disorder and its symptoms.

Nancy Foldvary-Schaefer, DO, FAAN, director of the Sleep Disorders Center and staff in the Epilepsy Center at Cleveland Clinic, discussed the recent advancements in narcolepsy treatments and the importance of incorporating a holistic care approach for patients.

During the open-label treatment period, 83% of patients with idiopathic hypersomnia who completed treatment saw a significant reduction in sleepiness, with an average Epworth Sleepiness Scale change of -9.4 points.